CELU Live signals | Maximize Profits with Getagraph.com

BUY 106699 min ago

@ $0.410

Issued: 12 Feb 2024 @ 16:00

Return: 636.59%

Live Chart Being Loaded With Signals

Commentary (26 Apr 2024 @ 16:00):

Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases...

Stats
Today's Volume	48 969.00
Average Volume	97 075.00
Market Cap	65.78M
EPS	$0 ( 2024-04-02 )
Next earnings date	( $-0.140 ) 2024-05-27
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.290
ATR14	$0.0240 (0.79%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-13	Fletcher Kyle	Sell	20	Class A Common Stock
2024-04-13	Haines John R	Sell	576	Class A Common Stock
2024-04-13	Beers David C	Sell	360	Class A Common Stock
2024-04-13	Hariri Robert J	Sell	1 154	Class A Common Stock
2024-04-13	Brigido Stephen	Sell	268	Class A Common Stock

INSIDER POWER
57.05
Last 98 transactions
Buy: 89 262 897 \| Sell: 26 354 903

Volume Correlation

Long: -0.01 (neutral)

Short: -0.26 (neutral)

Signal:(49.709) Neutral

Celularity Inc. Correlation

10 Most Positive Correlations
ASPS	0.945
AUID	0.931
CLFD	0.93
PROG	0.93
OP	0.927
AYLA	0.927
JUPW	0.925
PCSA	0.925
ADP	0.925
DWACU	0.923

10 Most Negative Correlations
CBAY	-0.935
TIOA	-0.926
CITE	-0.922
FXCO	-0.917
BWC	-0.915
XPDB	-0.915
BRIV	-0.914
TIOAU	-0.914
ROCL	-0.914
ITAQ	-0.912

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Celularity Inc. Correlation - Currency/Commodity

-0.48
( neutral )

-0.53
( weak negative )

0.00
( neutral )

-0.30
( neutral )

0.11
( neutral )

-0.16
( neutral )

Celularity Inc. Financials

Annual	2022
Revenue:	$17.98M
Gross Profit:	$-1.69M (-9.40 %)
EPS:	$1.010

FY	2022
Revenue:	$17.98M
Gross Profit:	$-1.69M (-9.40 %)
EPS:	$1.010

FY	2021
Revenue:	$21.34M
Gross Profit:	$17.69M (82.90 %)
EPS:	$-12.49

FY	2020
Revenue:	$0.00
Gross Profit:	$0.00 (0.00 %)
EPS:	$-0.0215

Financial Reports:

No articles found.

Celularity Inc.

Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, a placental-derived CAR-T therapy, which is in Phase I clinical trial for the treatment of B-cell malignancies; CYNK-001, placental-derived unmodified natural killer (NK) cell that is in Phase I clinical trial to treat acute myeloid leukemia, as well as in Phase I/IIa clinical trial for the treatment of glioblastoma multiforme and COVID-19; CYNK-101, an allogeneic genetically modified NK cell, which is in Phase I clinical trial to treat HER2+ gastric and gastroesophageal cancers; APPL-001, a placenta-derived mesenchymal-like adherent stromal cell that is in a pre-clinical stage for the treatment of Crohn's disease; and PDA-002, a placenta-derived mesenchymal-like adherent stromal cell, which is in pre-clinical stage for the treatment of facioscapulohumeral muscular dystrophy. It also sells and licenses products that are used in surgical and wound care markets, such as Biovance and Interfyl; collects stem cells from umbilical cords and placentas; and provides cells storage under the LifebankUSA brand. The company was incorporated in 2016 and is headquartered in Florham Park, New Jersey.